GlassScriptPhysician profile
Jessie Creakbaum
NPI 1295107597
$2,839.24
in general payments reported to CMS, 2019-2025
24 companies · $458 in 2025
The $458 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $238 · 2022: $742 · 2023: $734 · 2024: $667 · 2025: $458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,859.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,859.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $810.43 | 2021-2025 | |
| Novo Nordisk INC | $469.45 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $228.31 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $163.50 | 2022-2024 | Airsupra, Farxiga |
| Sanofi-Aventis U.S. LLC | $142.08 | 2021-2022 | |
| Lilly USA, LLC | $113.21 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Abbott Laboratories | $103.71 | 2024-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $99.48 | 2021-2024 | Shingrix, Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $92.71 | 2022-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $83.17 | 2022-2024 | |
| Idorsia Pharmaceuticals US INC | $61.80 | 2022-2023 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.56 | 2023-2025 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $60.42 | 2023-2024 | Uptravi, Opsumit |
| Amgen INC. | $51.91 | 2022-2023 | Otezla, Repatha |
| Biohaven Pharmaceutical Holding Company LTD. | $49.41 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $45.88 | 2024-2025 | Spravato, Xarelto |
| Exact Sciences Corporation | $41.59 | 2023-2024 | Cologuard Collection Kit |
| Astellas Pharma US INC | $38.39 | 2023-2024 | Veozah |
| Corcept Therapeutics | $27.58 | 2025 | Korlym |
| Sanofi Pasteur INC. | $23.94 | 2023 | |
| Stryker Corporation | $21.79 | 2025 | Clottriever Bold Catheter |
| Esperion Therapeutics, INC. | $18.60 | 2021 | |
| Boston Scientific Corporation | $15.91 | 2023 | Watchman Flx |
| Takeda Pharmaceuticals U.S.A., INC. | $15.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessie Creakbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.